Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).
Sponsor: Amphia Hospital
This PHASE4 trial investigates Myocardial Infarction and STEMI and is currently completed. Amphia Hospital leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Aug 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE4
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — May 2018 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Jan 2017 — Oct 2017 [monthly]
Unknown Status PHASE4
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amphia Hospital
- Federico II University
- Isala
- Meander Medical Center
- OLVG
- Onze Lieve Vrouw Hospital
- Rijnstate Hospital
- UMC Utrecht
- University Medical Center Groningen
- Vera HM Deneer
- ZonMw: The Netherlands Organisation for Health Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .